The BLM-3AB challenge assay: a micronuclei-based method for measuring DNA Repair Capacity
Keywords:
challenge assay, DNA repair, mutagen sensitivity, micronuclei, population monitoringAbstract
Efficient DNA repair activity is critically important in maintaining genomic integrity and reducing the risk of cancer. Hence, having sensitive DNA repair functional assays can be useful for identifying such abnormality and can be applied to risk prediction and disease prevention. We have developed a version of the challenge assay to measure DNA repair capacity. The assay is based on the cytochalasin B-micronucleus assay, with DNA damage induced by bleomycin and the subsequent DNA repair mechanism inhibited by 3-aminobenzamide. We used the assay to measure the DNA repair capacity of five vinyl chloride-exposed workers, five benzene-exposed workers and five healthy controls. We found that the DNA repair capacity in both vinyl chloride and benzene-exposed populations were higher than the controls, the mean index being 0.12, 0.16 and 0.54, respectively. For each individual, the micronuclei (MN) frequency of the baseline, being treated with bleomycin only and bleomycin + 3-aminobenzamide (BLM-3AB) together increased gradually. These data support the feasibility of the assay. In conclusion, our assay provides a new tool to identify DNA repair capacity of different individuals and may be applied in pathogenic mechanism-related research, especially occupational-related carcinogenesis.Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.